The stock of Collegium Pharmaceutical Inc (NASDAQ:COLL) is a huge mover today! About 413,310 shares traded hands or 27.38% up from the average. Collegium Pharmaceutical Inc (NASDAQ:COLL) has risen 6.57% since March 2, 2016 and is uptrending. It has underperformed by 1.69% the S&P500.
The move comes after 7 months negative chart setup for the $448.04M company. It was reported on Oct, 5 by Barchart.com. We have $16.26 PT which if reached, will make NASDAQ:COLL worth $62.73M less.
Analysts await Collegium Pharmaceutical Inc (NASDAQ:COLL) to report earnings on November, 10. They expect $-1.06 EPS, down 130.43% or $0.60 from last year’s $-0.46 per share. After $-1.05 actual EPS reported by Collegium Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 0.95% negative EPS growth.
Collegium Pharmaceutical Inc (NASDAQ:COLL) Ratings Coverage
Out of 2 analysts covering Collegium Pharmaceutical Inc (NASDAQ:COLL), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Collegium Pharmaceutical Inc has been the topic of 2 analyst reports since February 19, 2016 according to StockzIntelligence Inc. The rating was initiated by Gabelli on Tuesday, September 13 with “Buy”. The rating was initiated by William Blair with “Outperform” on Friday, February 19.
According to Zacks Investment Research, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States.”
More recent Collegium Pharmaceutical Inc (NASDAQ:COLL) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on April 19, 2015. Also Streetinsider.com published the news titled: “Collegium Pharma (COLL) Announces Submission of Xtampza ER SNDA to U.S. FDA” on October 05, 2016. Fool.com‘s news article titled: “Why Collegium Pharmaceutical Is Rocketing Higher Today” with publication date: September 14, 2015 was also an interesting one.
COLL Company Profile
Collegium Pharmaceutical, Inc., incorporated on July 01, 2014, is a specialty pharmaceutical company. The Firm focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.